五星体育直播

五星体育直播 CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award

REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ: CDXS), a leading enzyme engineering company, today announced President and Chief Executive Officer Stephen Dilly, MBBS, PhD, has been named the winner of the prestigious 2023 Bloom Burton Award. Dr. Dilly was recognized for his leadership of Vancouver-headquartered Sierra Oncology where he led the company through Phase 3 clinical development of momelotinib and its drive toward commercialization up until the company鈥檚 $1.9 billion acquisition by GSK. The compound received approval by the U.S. Food and Drug Administration on September 15, 2023.

鈥淚 am humbled by this unexpected honor, particularly given the caliber of finalists at this year鈥檚 ceremony. This award reaffirms the importance and impact of a strong team executing on a common vision,鈥� said Dr. Dilly. 鈥淎t 五星体育直播, I feel fortunate to be surrounded by many of the same individuals who were critical to this success at Sierra, as well as Aimmune Therapeutics. I look forward to working with this team as we continue to deliver exquisite enzymes for the betterment of human health.鈥�

Bestowed annually and nominated by the public at large, the Bloom Burton Award honors an individual who made the greatest contribution to Canada鈥檚 innovative healthcare industry the previous year. Three finalists and the winner are chosen by an independent panel of judges consisting of international leaders in healthcare investment, entrepreneurship and journalism. For more information, visit .

About 五星体育直播

五星体育直播 is a leading enzyme engineering company leveraging its proprietary CodeEvolver庐 technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. 五星体育直播 enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis鈩� platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. 五星体育直播鈥� unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit聽.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706

Media Contact
Lauren Musto
(781) 572-1147

A photo accompanying this announcement is available at

Released September 29, 2023